Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Cabotegravir

An HIV integrase inhibitor, blocking the enzyme the virus uses to insert its genome into human DNA. It was approved in 2020 and 2021 for treatment, together with rilpivirine, and in 2021 in the United States for prevention as well. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?Injected into muscle it has a half-life of weeks, compared with about 41 hours for the tablets: with rilpivirine it was the first antiretroviral available as a long-acting injection.

CabotegravirGo to the active ingredient →
CabotegravirActive ingredientCabotegravirCat. No. P-C003-001CAS 1051375-10-0

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.